Skip to main
LUCD

Lucid Diagnostics (LUCD) Stock Forecast & Price Target

Lucid Diagnostics (LUCD) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Lucid Diagnostics is an attractive investment opportunity, with a large potential market of millions of patients facing the risk of developing esophageal cancer. The company's EsoGuard and EsoCheck products have shown promising results in detecting Barrett's Esophagus and Esophageal Adenocarcinoma, and the positive sentiment from Medicare's Contractor Advisory Committee meeting in September 2025 indicates potential future coverage and reimbursement. Although there is risk associated with the company's commercialization efforts and competitive landscape, the potential for high rewards and the company's progress on securing Medicare coverage make for a positive outlook.

Bears say

Lucid Diagnostics is a commercial-stage medical diagnostics company, focusing on patients with gastroesophageal reflux disease (GERD) through their EsoCheck and EsoGuard products. While the market potential for these products is large, the long commercialization and growth challenges ahead present risky prospects for investors. Additionally, the high revenue CAGR and EV/sales multiple in the bull case scenario may not be achievable.

Lucid Diagnostics (LUCD) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Lucid Diagnostics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Lucid Diagnostics (LUCD) Forecast

Analysts have given Lucid Diagnostics (LUCD) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Lucid Diagnostics (LUCD) has a Strong Buy consensus rating as of Apr 30, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4.12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4.12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Lucid Diagnostics (LUCD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.